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OBJECTIVES This study evaluated changes in antithrombin (AT) activity around the time of percutaneous
transluminal coronary revascularization (PTCR) with unfractionated heparin anticoagulation
and the effects these changes had on major thrombotic complications of PTCR.
BACKGROUND Heparin is used during PTCR to prevent thrombosis. However, heparin, a cofactor for AT,
causes AT activity to fall. AT activity ,70% is associated with thrombosis. There is a
prothrombotic state after heparin discontinuation that has not been well explained.
METHODS Antithrombin activity was sampled at the start and end of PTCR and the next two mornings
in 250 consecutive patients. We recorded occurrence of major thrombotic events, defined as
1) major thrombotic complications of PTCR; 2) major in-lab thrombus formation; or 3)
subacute occlusion. Discriminant analysis was employed to evaluate the relationship of AT
activity to these events. Change in AT activity and its relationship to heparin was evaluated.
Evidence of restenosis at six months was obtained.
RESULTS There were 14 major thrombotic events. Antithrombin activity ,70% was strongly (p 5
0.006) associated with these events. The AT activity fell significantly through the morning
after PTCR when 21% of patients had AT activity ,70%; AT activity did not normalize until
.20 h after heparin discontinuation. Pre-PTCR use of heparin led to lower AT activity in
proportion to duration of heparin use. There was no relationship between AT activity and
restenosis.
CONCLUSIONS Low AT activity may contribute to major thrombotic complications of PTCR. The way
heparin is used before and after PTCR is important to development of low AT activity.
(J Am Coll Cardiol 1999;33:1248–56) © 1999 by the American College of Cardiology
Intense anticoagulation during percutaneous transluminal
coronary revascularization (PTCR) is required to minimize
the risk of thrombotic complications during and shortly
after the procedure. This anticoagulation is almost univer-
sally accomplished with heparin. In addition, heparin pre-
treatment for several days has been suggested to reduce the
chance of an adverse outcome, especially in the subset of
patients with unstable angina (1). When heparin is discon-
tinued, a transient hypercoagulable state has been described
that has not been well explained (2–4).
Heparin has indirect antithrombotic activity; it functions
as a cofactor for antithrombin (AT), increasing the activity
of that molecule 1000-fold. However, treatment with hep-
arin causes AT levels to fall (5–7), and AT deficiency has
been associated with thrombosis (8). The effects of heparin
on AT activity around the time of PTCR and the clinical
implications of these effects on the results of PTCR,
particularly with respect to thrombotic complications, have
not been evaluated.
METHODS
Patient sample. Two hundred fifty consecutive patients
undergoing PTCR by the faculty at Cooper Medical Center
were enrolled between May 18 and December 22, 1994.
Elective, urgent, and emergent procedures were included.
Patients were enrolled regardless of the type of procedure
planned or actually undertaken. However, if a procedure was
unsuccessful owing to inability to cross the lesion with a
wire and balloon, that patient was removed from the
protocol.
The protocol was approved by the Institutional Review
Committee of Cooper Medical Center. Because the proto-
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col did not affect the angioplasty procedure in any way, no
investigational drug or device was used as part of the
protocol, and only minimal extra phlebotomy was required
by the protocol, individual informed consent was not
required.
Angioplasty procedure. The angioplasty procedure was
not affected by the protocol in any way. All patients were on
antiplatelet therapy at the time of PTCR, consisting of
aspirin or, in the few patients with aspirin allergies, ticlo-
pidine. An activated clotting time (ACT; Hemochron,
Technidyne, Edison, New Jersey) of greater than 250 s was
confirmed prior to the first dilation. Additional heparin was
administered to achieve a goal ACT of 300 to 350 s. The
ACT was recorded at the conclusion of the procedure at
which time mean ACT was 339 6 64 s, and 75% of the
population had an ACT greater than 300 s. The type of
revascularization procedure performed (balloon, stent, laser,
directional atherectomy) was determined by the attending
interventional cardiologist. At the time of this protocol,
stents were generally placed only for threatened closure or
inadequate PTCR result and not as primary therapy. Either
a noncalcium chelating form of meglumine diatrizoate
(Hypaque 76™), a high-osmolality contrast agent, or io-
hexol (Omnipaque™), a nonionic low osmolality agent, was
used as contrast media. Heparin therapy prior to PTCR was
at the discretion of the attending cardiologist, but duration
of heparin therapy prior to the procedure was recorded.
Arterial and venous sheaths were generally maintained in
place the night after PTCR with a goal aPTT of 65 to 100 s.
Heparin was discontinued the following morning for sheath
removal and was restarted following sheath removal at the
discretion of the attending cardiologist.
Antithrombin sampling. Blood samples were drawn from
the unheparinized venous sheath at the beginning of PTCR,
at the end of PTCR and the following morning just before
heparin was discontinued for sheath removal. A fourth
sample was drawn the second morning after PTCR from a
fresh venupuncture if the patient was still hospitalized. The
AT activity was measured with a chromogenic assay using
anti-Xa activity (Chromogenix, Molndel, Sweden) on an
MLA 1000 (Medical Laboratory Automation, Pleasantville,
New York) with an established reference interval of 76% to
138%. All specimens were run on the same lot of reagent.
An AT activity ,70% was defined as clinically important
(8).
Clinical outcome events. Primary clinical outcome events
are defined in Table 1. These events were chosen because
they are thrombotic complications with clinical significance.
In addition, they were chosen because they are all angio-
graphic events and are less subjective than either evidence of
thrombus at the PTCR site not severe enough to require
additional intervention or postprocedure chest pain without
angiographic correlation. Thrombus was defined as a filling
defect surrounded by contrast. Events that were clearly due
to major coronary dissections, such as long spiral dissec-
tions, were not included as end point events. All events were
reviewed by two investigators with no knowledge of AT
activity, and if it was believed that thrombus could be
playing a role in the event, that event was counted as a
thrombotic event. Patients were followed until discharge
after PTCR, and only events during that hospitalization
were included in the analysis.
A secondary end point was restenosis at six months,
which was defined either angiographically or clinically.
Restenosis was defined angiographically as cross-sectional
diameter stenosis .50% at the site of the PTCR. Clinical
restenosis was defined as cardiac death, myocardial infarc-
tion in the distribution of the dilated artery or evidence of
ischemia on stress testing in the distribution of the dilated
artery. Angiographic follow-up or stress testing was not
required by the protocol.
Statistical analysis. Continuous variables were analyzed
with the Student t test for normally distributed continuous
variables and with the Mann-Whitney U test for variables
not normally distributed. Repeated measures of continuous
variables were analyzed by repeated measures analysis of
variance (ANOVA), and the Newman-Keuls procedure was
used to evaluate differences between groups. Chi-square
analyses were used for discrete variables. Repeated measure-
ments of discrete variables were evaluated with Cochran’s
Q; the McNemar test with a Bonferroni correction was used
to evaluate differences between groups. Independent vari-
ables that were significantly related to the occurrence of an
outcome event were included in a discriminant analysis,
which was done using the discriminant procedure of the
SPSS-X statistical package with cutoffs of p 5 0.3 for
Abbreviations and Acronyms
ACT 5 activated clotting time
AT 5 antithrombin
PTCR 5 percutaneous transluminal coronary
revascularization
Table 1. Primary Clinical Outcome Events
I. Major complications of PTCR due to thrombotic occlusion
Q-wave myocardial infarction
Emergent bypass surgery
Death
II. Major new thrombus formation during the procedure
leading to:
Acute occlusion OR
Thrombus accumulation and TIMI 1–2 flow and need for
further therapy (redilation, thrombolysis)
III. Subacute occlusion after procedure (must be documented
angiographically)
TIMI 5 Thrombolysis in Myocardial Infarction Study.
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entering and removing variables from the model. The
significance of the F to remove at the last step provided p
values for the variables in the model. Results were analyzed
by patient and not by lesion because the major point of
interest, AT activity, is not independent between two
lesions in the same patient. If a patient had more than one
lesion dilated, either the first lesion dilated or the lesion
with an outcome event was used for analysis. In no case was
there more than one outcome event in a single PTCR
procedure.
RESULTS
Patient sample and primary outcome events. Two hun-
dred fifty consecutive patients undergoing PTCR were
successfully enrolled in the protocol, and 310 lesions were
dilated. Patient demographics and procedures performed are
outlined in Table 2. Antithrombin activity was measured in
245 patients before PTCR, 246 at the end of the procedure,
and in 242 and 200 on the first and second mornings after
the procedure, respectively.
There were 14 primary outcome events. Nine patients
had acute, in-lab thrombotic occlusion or reduced coronary
flow due to angiographically present thrombus that required
further treatment. There were three cases of out-of-lab
subacute closure. One patient had failed PTCR due to the
requirement of emergency bypass surgery, and one patient
died suddenly from cardiac causes the day after PTCR.
Antithrombin activity. As seen in Figure 1, for the sample
as a whole, mean AT activity declined over the course of the
procedure, declined further as heparin was continued the
evening of PTCR, and rose toward baseline between the
first and second morning after the procedure when heparin
had been discontinued in many of the patients. A significant
difference occurred across the four time periods (p , 0.001,
repeated measures ANOVA) and between each and every
other point (p , 0.05, Newman-Keuls procedure). The
percent of patients with AT activity ,70%, a range believed
to confer clinical importance, is shown in Figure 2. There
was a significant difference (p , 0.05, Cochran’s Q) across
the four time periods, and more patients had AT activity
Table 2. Clinical, Angiographic and Procedural Characteristics
Number
(n 5 250 patients,
310 lesions) %
Gender
Male 186 74.4
Female 64 25.6
Diagnosis
Stable angina 28 11.2
Unstable angina 125 50.0
Post-MI 85 34.0
Other 12 4.8
Cardiac risk factors
Diabetes 51 20.4
Hypertension 146 58.4
Hypercholesterolemia 136 54.4
Smoking 171 68.4
Number of diseased
coronary arteries
1 143 57.2
2 75 30.0
3 or left main 32 12.8
Number of sites dilated
1 196 78.4
2 48 19.2
$3 6 2.4
Procedures performed
Balloon PTCR 283 91.3
Bailout stent 16 5.2
Planned stent 4 1.3
Directional atherectomy 1 0.3
Holmium laser 2 0.7
Dispatch catheter 4 1.3
Figure 1. Mean antithrombin activity (6SD) for the patient
sample at the four points at which antithrombin activity was
determined. Mean AT activity at each time point was significantly
different from every other time point.
Figure 2. Percent with antithrombin activity ,70% for the patient
sample at the four points at which antithrombin activity was
determined. The percentage of patients with AT ,70% was
significantly greater post-PTCR and the next morning than
pre-PTCR. *p , 0.001 vs. Pre PTCR.
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,70% after PTCR and the following morning than before
PTCR (p , 0.001, McNemar’s test). An AT activity ,70%
was measured in 29.2% of the population in at least one
sample. There was no relationship between the type of
procedure performed or choice of contrast agent and AT
activity.
Antithrombin activity was lower in those who received
preprocedural heparin, and the degree of decline was di-
rectly related to the duration of time that a patient was on
heparin prior to the start of the procedure (Table 3). Not
only was this finding true for the mean AT activity at the
start of PTCR, but mean AT activity at the end of the
procedure and the morning after PTCR was also lower the
longer a person had been on preprocedural heparin. When
the incidence of AT activity ,70% is analyzed, results are
similar; the longer a patient was on heparin prior to PTCR,
the more likely that AT activity would be ,70%. There
were 22 patients who started the PTCR procedure with an
AT activity ,70%; 21 of those 22 patients had received
heparin for greater than 48 h prior to the procedure.
There is a more rapid drop in AT activity over the course
of the PTCR procedure itself than in other periods of
similar duration. The mean decrease in AT activity was
7.5% over the 1 to 2 h of the procedure (90.1 6 18.0% to
82.6 6 15.8%) and only 4.1% in the period from the end of
the procedure to the next morning (82.6 6 15.8% to 78.5 6
12.9%). Forty-one patients had AT activity ,70% by the
end of PTCR. The change in AT activity during the
procedure was independent of the time the patient had been
exposed to heparin prior to the procedure.
Heparin was discontinued in all patients before sheath
removal, generally the morning after PTCR. In 194 pa-
tients, heparin was restarted shortly thereafter based on the
angiographic appearance of the PTCR result or for other
clinical indications and was continued for variable periods of
time. In many patients, heparin was discontinued before the
AT level was drawn on the second morning after PTCR,
allowing us to examine recovery of AT activity after discon-
tinuation of heparin (Fig. 3). The AT activity gradually
returned toward normal, but mean AT activity continued to
be significantly less than normal unless heparin had been
discontinued for more than 20 h.
Association of outcome events and antithrombin activity.
Univariate association of AT activity with primary outcome
events is shown in Table 4. There was a strong association
of AT activity ,70% with a thrombotic event, and mean
AT activity was lower in those patients with events than in
those without events. The association of other variables with
outcome events is shown in Table 5. The presence of
thrombus at the start of PTCR and use of nonionic contrast
media were particularly strongly associated with these
thrombotic events. Although AT activity ,70% was de-
fined as the critical level in the protocol and all analyses used
this level, secondary analysis reveals that AT activity below
the reference range of the laboratory (,76%) was measured
in 11 of 14 patients in the sample drawn closest to the event.
Antithrombin activity ,70% was measured in 10 of 14
patients with an event (Table 4) and of these 10, it was
drawn in the sample taken closest to the event in 6 patients.
In the other four patients, it was 75% or less in the sample
drawn closest to the event.
Independent variables related to outcome events by uni-
variate analysis were included in a multivariate analysis to
clarify further the role these variables played in the occur-
rence of thrombotic events. Many of the variables with a
univariate relationship to a primary outcome event were not
independent of each other, and therefore many of these
Table 3. Relationship of Preprocedural Heparin to Antithrombin Activity
Duration of
Preprocedure Heparin
Mean Antithrombin Activity (%)
Patients with Antithrombin
<70%/Total Number
Start of
PTCR
End of
PTCR Next AM
Start of
PTCR
End of
PTCR Next AM
None 99.7 6 17.3 90.4 6 13.2 83.4 6 11.8 0/82 2/83 7/81
0–6 h 95.7 6 16.5 88.6 6 13.9 79.1 6 10.7 0/23 1/21 4/23
6–12 h 92.8 6 14.2 86.7 6 14.2 81.2 6 12.7 0/10 0/10 1/10
12–24 h 89.2 6 13.5 82.8 6 12.8* 75.8 6 10.6 1/13 3/13 4/13
24–48 h 88.2 6 12.6* 81.5 6 11.0* 79.8 6 10.2 0/22 3/22 4/22
.48 h 80.9 6 16.2* 74.4 6 15.8* 73.8 6 13.8* 21/96† 32/96† 31/93†
*p , 0.05 vs. no preprocedure heparin by Newman-Keuls procedure; p , 0.001 across all time periods by repeated measures analysis of variance. †p , 0.001 by trend chi-square.
Figure 3. Recovery of antithrombin activity from the time of
heparin discontinuation. Antithrombin activity remained signifi-
cantly less than normal until heparin had been discontinued for
more than 20 h. *p , 0.05 vs. normal.
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variables were not included in the multivariate analysis. In
particular, the presence of thrombus at the start of PTCR,
a diagnosis of unstable angina or recent infarction, and use
of preprocedural heparin were all strongly related to each
other. A discriminant analysis with AT activity (as a
dichotomous variable, ,70% or $70%), presence or ab-
sence of thrombus at the start of the procedure, contrast
agent used (nonionic or ionic), initial percent stenosis, and
lesion length (#10 mm or .10 mm) were included in the
analysis. The occurrence of AT activity ,70% at any time
continued to be strongly associated with outcome events
(p 5 0.006). Use of nonionic contrast (p 5 0.0002),
thrombus before PTCR (p 5 0.02), and lesion length (p 5
0.02) also continued to have a statistically strong relation-
ship to these major thrombotic events.
Not surprisingly, the population with AT activity ,70%
was more likely to have unstable angina or recent infarction
than were those with AT activity $70%. Clinically, this is
the population in whom heparin use would be expected.
Other than a greater likelihood of high cholesterol in those
with AT activity ,70% (p 5 0.045), there were no
differences in clinical variables between the two groups.
Restenosis. Six-month follow-up was available in 93% of
the study sample. Angiographic follow-up was obtained in
59 patients (23.6%). There was clinical or angiographic
evidence of restenosis in 24%. There was no relationship
between AT activity and restenosis (Table 6).
DISCUSSION
This study is the first to examine and demonstrate a
strong correlation between AT activity during the period
of angioplasty and major thrombotic complications of
that procedure. We have demonstrated that AT activity
declines by an unexpectedly large amount during the
PTCR procedure itself and continues to decline over the
evening after PTCR when heparin is continued. In a
significant percentage of this population, AT activity
drops to a level that is considered clinically important.
The degree that AT activity is lower than normal when
measured before, just after or the morning after PTCR is
directly correlated with the duration of preprocedure
heparin. Following discontinuation of heparin, AT activ-
ity recovers slowly and remains lower than normal during
the same period in which a relative hypercoagulable state
has been demonstrated in other studies after the discon-
tinuation of heparin. This study also confirmed the
deleterious impact preprocedural thrombus (9) and lesion
length (10) have on outcome, and we have added evi-
dence to support the contention that use of low osmola-
lity nonionic contrast media in angioplasty may be
associated with thrombotic complications (11).
Low AT activity and reduced local antithrombotic effect.
Low AT activity may lead to reduced local anticoagulant
effect at the time of PTCR. Although it is widely recognized
that the effect of the heparin/AT complex on clot-bound
thrombin (12,13) or on thrombin bound to soluble fibrin
(14) is less than that on fluid-phase thrombin, it is impor-
tant to understand that this is a relative effect and that
inhibitory activity continues to increase as heparin concen-
tration increases. Therapeutic heparin concentrations of 0.2
to 0.4 U/ml completely inhibit fluid-phase thrombin but
only produce 20% to 40% inhibition of clot-bound throm-
bin, but a heparin concentration of 2 U/ml will inhibit 70%
of clot-bound thrombin (12). In another study, growth of
thrombus on damaged porcine carotid artery in the presence
of fresh thrombus was inhibited in direct proportion to the
dose of administered heparin up to the point of 100%
inhibition at very high doses (13).
Because both heparin and AT are required for an
effective antithrombotic effect, we theorize that if either
AT or heparin concentration is inadequate, expected
anticoagulation may not result. Perhaps the full benefit of
AT-dependent therapy cannot be realized unless AT is
adequate at the PTCR site. Whereas heparin concentra-
tion in the peri-PTCR period may be sufficient to easily
inhibit fluid-phase thrombin as reflected in an elevated
ACT, low AT activity may result in inadequate inhibi-
tion of clot bound thrombin with resultant local ongoing
thrombus generation and platelet activation at the site of
PTCR. Heparin concentration at the PTCR site may be
adequate, but low AT activity may lead to local throm-
bosis even in the setting of continued systemic heparin
Table 4. Association of Antithrombin Activity With Primary Outcome Events
Number of Patients (% of group)
With Antithrombin <70% Mean Antithrombin Activity 6 SD
Group With
an Event
Group With
No Event
Group With
Event
Group With
No Event
Pre-PTCR 3 (23.1%) 19 (8.2%) 82.0 6 16.4% 90.6 6 18.0%
Post-PTCR 5 (35.7%) 36 (15.6%) 74.0 6 14.7%* 83.1 6 15.7%
Next AM 6 (54.5%)* 45 (19.5%) 69.8 6 10.3%* 78.9 6 12.9%
Following AM 5 (50.0%)* 18 (9.5%) 72.2 6 14.2%* 87.6 6 16.6%
At any time 10 (71.4%)† 63 (26.7%) — —
*p , 0.05 vs. group with no event; †p 5 0.001 vs. group with no event.
SD 5 standard deviation.
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anticoagulation. Heparin-resistant thrombin activity,
manifested as elevated coronary sinus fibrinopeptide A
levels, has been associated with angiographic evidence of
coronary thrombus and ischemic complications of PTCR
(15). Patients with threatened or abrupt coronary occlu-
sion during PTCR have been shown to have elevated
local thrombin activity when compared with those with-
out an event despite similar heparin concentrations and
ACT (16). Experimental models evaluating heparin effect
have been performed only in the presence of normal AT
activity, but increased antithrombotic effects have been
shown to be directly related to dose of administered AT
in vitro (17). Neither low AT activity in the presence of
high heparin concentrations nor the effects of high AT
levels in the presence of stable heparin concentrations
have been studied.
Table 5. Univariate Association of Clinical, Angiographic, and Procedural Variables With
Primary Outcome Events
Continuous
Variables n Event No Event p-Value
Lesion severity 250 94.8% 87.5% 0.004
Normal vessel size 250 3.36 mm 3.13 mm 0.15
Discrete Variables
Total No. With
Characteristic
No. With
Event % p-Value
Thrombus at start
Yes 31 11 35.4 ,0.001
No 219 3 1.4
Contrast agent
Ionic 153 1 0.7 ,0.001
Nonionic 97 13 13.4
Lesion length
#10 mm 158 5 3.2 0.03
.10 mm 92 9 9.8
Patient diagnosis
Stable angina 28 0 0 0.001
Unstable angina 125 2 1.6
Post-MI 85 9 10.6
Other 12 3 25
Heparin pre-PTCR
None 85 1 1.2 0.15
0–6 h 23 4 17.4
6–12 h 10 0 0
12–24 h 13 1 7.7
24–48 h 22 1 4.5
.48 h 97 7 7.2
Gender
Male 186 13 7.0 0.19
Female 64 1 1.6
Site angulation
,45 degrees 220 11 5.0 0.46
45–90 degrees 23 2 8.7
.90 degrees 7 1 14.3
Ulceration at start
Yes 22 3 13.6 0.22
No 228 11 4.8
Radial symmetry
Concentric 113 3 2.7 0.12
Eccentric 137 11 8.0
Calcified lesion
Yes 54 1 1.9 0.31
No 196 13 6.6
Major branch involvement
Yes 43 4 9.3 0.43
No 207 10 4.8
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Effects of heparin on AT activity. The effects of standard
doses of heparin on AT levels have been evaluated in small
studies with conflicting results (5–7). Although it has been
suggested that AT levels fall rapidly after heparin adminis-
tration but do not continue to decline and that they recover
rapidly after heparin discontinuation (7), the current study
confirms the findings of Marciniak (5) and Rao et al. (6)
that AT activity declines progressively over at least the first
several days of heparin therapy and recovers relatively slowly
after heparin discontinuation.
The progressive decline in AT activity over 48 h and slow
recovery may have clinical relevance to management of
patients about the time of PTCR. Clinical studies evaluat-
ing heparin use prior to PTCR have produced conflicting
results. Laskey et al. (1) suggested that 48 h of preproce-
dural heparin reduces the incidence of periprocedural com-
plications in patients with unstable angina or visible throm-
bus (18), whereas Klein et al. (19) found that the group that
had more than 48 h of preprocedural heparin had more
complicating myocardial infarctions and deaths. Our study
shows that patients who receive heparin for greater than
48 h have significantly lower AT activities than do those
with a shorter duration of pre-PTCR heparin; this suggests
that extended infusions of heparin prior to PTCR may be
detrimental in some patients owing to the effects of heparin
on AT. In addition, prolonged heparin therapy after PTCR
may lead to further decline in AT activity, supporting the
current practice of early heparin discontinuation after
PTCR, although there are no good data to suggest this
practice may reduce thrombotic events.
There is a period of relative hypercoagulability following
discontinuation of heparin therapy in acute coronary syn-
dromes (2–4). Our data have shown that AT activity
remains lower than normal over this prothrombotic period
after heparin discontinuation, raising the possibility that low
AT activity may be playing a role in this prothrombotic state
and in those patients with thrombotic events after PTCR.
Each of the four patients in our study with events after
PTCR had AT activity ,70% before the event. D-dimer
levels, which are markers of thrombin activity, have been
shown to be lower in patients in whom AT activity was
normalized with AT concentrates prior to discontinuation
of heparin than in those in whom AT activity was not
normalized (20).
Our findings unexpectedly demonstrate a surprisingly
large fall in AT activity during the PTCR procedure itself.
The AT levels do not drop during PTCR with direct
thrombin inhibitors (21), suggesting that the procedure
itself does not cause AT levels to fall. We cannot exclude the
possibility that the marked decrease in AT activity seen may
be explained by the very large doses of heparin used during
PTCR, but Rao et al. (6) showed that a 100 U/kg heparin
bolus did not cause AT levels to decline. Our data raise the
possibility that the large decrease in AT activity from the
start to the end of PTCR may be due to other mechanisms
unique to PTCR with heparin anticoagulation, which may
increase AT clearance or consumption and may increase the
risk of thrombosis. The large decline in AT activity over the
course of the procedure itself explains why prolonged
heparin infusion alone was not a predictor of a thrombotic
event.
Antithrombin and restenosis. The lack of long term
benefit on the incidence of restenosis is consistent with
other trials of antithrombotic therapy. Reduction of local
thrombus formation with any number of antithrombotic
agents, including hirudin (22,23) and AT (24), has reduced
restenosis in animal models, but these benefits have not
been confirmed in clinical studies (25,26). The mechanism
of restenosis is multifactorial, and any role for antithrom-
botic therapy has yet to be defined.
Study limitations. The major limitation of this study is the
lack of confirmatory evidence that the thrombotic events
that occurred were a result of low AT activity. It is our
hypothesis that low AT activity reduces the effect of heparin
on clot-bound thrombin. These data cannot answer those
questions. It is well documented that low AT activity is
associated with a systemic hypercoagulable state in other
populations (8,27), but low AT activity in those populations
may not have the same effect as low AT activity in this
population. Nevertheless, we hypothesize that a systemic
hypercoagulable state is not a prerequisite to the thrombotic
events we have reported; inadequate AT activity at the
PTCR site may result in a local hypercoagulable state. If low
AT activity is not the primary cause of the thrombotic
events, it appears to be, at the least, a marker of increased
risk. Once validated, low AT activity may guide a physician
toward more aggressive antithrombotic therapy in the pe-
riod around PTCR.
Demonstration of a strong relationship between AT
activity and these thrombotic events could be achieved if
administration of AT concentrates or other antithrombotics
was shown to reduce the incidence of thrombotic compli-
cations in those with low AT activity. Antithrombin con-
centrates have been used in two studies of PTCR. Schach-
inger and colleagues (28) showed that a mean dose of 730 U
of AT did not reduce the incidence of thrombotic events in
patients undergoing PTCR. The AT activity was not
measured during this trial, and the infusion rate of AT used
would not be expected to normalize a low AT activity. In a
trial of 50 PTCR patients with unstable angina, Grip et al.
Table 6. Relationship of Restenosis and Antithrombin Activity
Percent With Antithrombin <70%
Restenosis
No
Restenosis
Pre-PTCR 6.1 8.6
Post-PTCR 14.3 16.2
Next AM 28.6 17.3
Following AM 6.1 8.6
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(20) administered either placebo or AT with a goal AT
activity of 120%. They found no difference in clinical events
or in acute markers of coagulation activation but did find
that thrombin activation after discontinuation of anticoag-
ulation as measured by the D-dimer was less pronounced in
the population that received AT. Inadequate AT may have
been given in the first trial, and the second trial was not
powered to evaluate the clinical significance of AT supple-
mentation.
Conclusions. This study has shown a strong relationship
between low AT activity and major thrombotic complica-
tions of PTCR. The effects of heparin therapy and PTCR
on AT activity in a large population have been carefully
evaluated, and the decline in AT activity was found to be
significant in a large portion. We believe these data may
explain, in part, thrombotic complications of PTCR. The
study has also raised a number of intriguing questions
regarding the role for measurement of AT activity as a
marker for patients at risk for thrombosis, for the appropri-
ate use of heparin or other antithrombotic agents before,
during, and after PTCR, and suggests that there may be a
role for AT administration in selected patients. It is likely
that unfractionated heparin will continue to be used for the
immediate future during PTCR and in the management of
acute coronary syndromes, and this study provides more
complete understanding of the effects of the antithrombotic
therapy in current usage.
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